Industry veterans Jennifer Rouse and Gina Collins join Autonomize AI as the company scales its AI-native platform across healthcare clients, including three of the five largest health plans
AUSTIN, Texas–(BUSINESS WIRE)–Autonomize AI, the pioneer in empowering healthcare enterprises to become AI-native organizations, today announced the appointment of two senior leaders to its executive team: Jennifer Rouse as VP of Marketing and Gina Collins as Chief Regulatory Officer. The appointments come as Autonomize AI accelerates adoption of its governed AI platform, empowering a growing number of organizations by delivering tens of millions of dollars in general and administrative savings, measurable ROI, and industry-leading time to value.
“We are at a pivotal moment in healthcare AI,” said Ganesh Padmanabhan, CEO and Co-Founder of Autonomize AI. “Our platform is delivering real, measurable results—tens of millions in G&A savings, faster decisions, and enterprise-scale deployments. Jennifer and Gina bring exactly the strategic depth and operational credibility we need in accelerating our next phase of growth.”
Jennifer Rouse — VP of Marketing
Jennifer Rouse joins Autonomize AI as VP of Marketing, bringing more than 20 years of B2B healthcare marketing leadership. Most recently, she served as Worldwide Head of Healthcare Marketing at AWS, leading global strategy to help healthcare organizations leverage cloud, data, and AI at scale. Previously, she held senior marketing roles at IBM and Cisco and served as a global analyst and advisor with Forrester Research, building deep expertise across cloud computing, cybersecurity, compliance, and AI.
“Jennifer knows how to translate complex platform value into clear, compelling narratives that move markets,” said Padmanabhan. “Her experience leading global healthcare marketing at AWS makes her an extraordinary fit as we define the AI-native healthcare category.”
Gina Collins — Chief Regulatory Officer
Gina Collins brings more than 20 years of executive leadership in healthcare operations, regulatory compliance, and risk management to her role as Autonomize AI’s Chief Regulatory Officer. She most recently served as Office Director at the FDA’s Center for Devices and Radiological Health. Prior to the FDA, Collins held senior operational roles at Cigna where she oversaw teams across operational excellence, risk and compliance
“Gina brings an extraordinary combination of healthcare regulatory experience and deep operational compliance leadership,” said Padmanabhan. “As our platform scales across the country’s largest health plans, her ability to harmonize strategy, operations, and alignment across compliance and regulations, helps ensure every AI-driven decision is transparent, defensible, and built on trust.”
Scaling Impact Across Healthcare’s Largest Enterprises
The appointments of Rouse and Collins follow a period of rapid growth for Autonomize AI. The company’s platform is now deployed across a growing number of leading healthcare organizations—live at three of the five largest U.S. health plans—powering AI-enabled workflows across utilization management, appeals and grievances, care management, claims operations, and payment integrity.
In a regulatory environment where CMS and other Administration priorities continue to evolve, Autonomize AI remains focused on helping customers navigate change with confidence. Our platform aligns with federal priorities related to care quality, administrative simplification, transparency, and responsible technology adoption.
Clients are reporting tens of millions of dollars in annual G&A savings, with deployment timelines as fast as 45–60 days—setting a new benchmark for time to value, scalability, and ROI in healthcare AI.
Autonomize AI’s $28 million Series A funding round, led by Valtruis, The Cigna Group Ventures, and existing investors Asset Management Ventures and ATX Venture Partners continues to fuel the company’s investment in platform innovation, enterprise-grade governance, and the talent needed to lead the emerging category of the AI-Native Healthcare Enterprise.
About Autonomize AI
Autonomize AI uses specialized AI Agents to simplify some of healthcare’s most complex and manual processes, transforming them into streamlined, AI-native operations. Our solutions reduce administrative bottlenecks in utilization management, care management, contracts, claims, and payments—blending automation with human expertise to deliver faster decisions, lower costs, and better patient experiences. Autonomize works with healthcare providers, payers, life sciences organizations, and digital health companies—including 3 of the 5 largest healthcare enterprises in the U.S. We are backed by top-tier venture capital, including Valtruis, Asset Management Ventures, Cigna Group Ventures ATX Venture Partners, and TAU Ventures.
For more information, please visit http://autonomize.ai.
Contacts
PR Contact
autonomize@avenuez.com
Avenue Z
